Xcovery Holdings, Inc.
Xcovery is a biopharmaceutical company focusing on improving the lives of patients with cancer. Xcovery is currently pursuing a global phase 3 registration trial of ensartinib, a next generation anaplastic lymphoma kinase (ALK) inhibitor, for first-line treatment of ALK positive non-small cell lung cancer. In addition, Xcovery is running phase 1/2 studies of vorolanib, an oral vascular endothelial growth factor receptors (VEGFRs) inhibitor, in combination with immune-oncology (IO) agents, in treating thoracic and gastrointestinal cancers.